The Effect of Early Spironolactone Administration on 2-Year Acute Graft Rejection in Cardiac Transplant Patients
Authors:
- Dragos-Florin BabaDBDragos-Florin Baba
- Alina DanilescoADAlina Danilesco
- Horatiu SuciuHSHoratiu Suciu
- Calin AvramCACalin Avram
- Marius Mihai HarpaMHMarius Mihai Harpa
- Mircea StoianMircea Stoian
- Diana-Andreea MoldovanDMDiana-Andreea Moldovan
- Laurentiu HumaLHLaurentiu Huma
- Gabriel RusuGRGabriel Rusu
- Tunde PalTPTunde Pal
- Adina StoianASAdina Stoian
- Anca-Ileana SinASAnca-Ileana Sin
Open Access
- 10 May 2025
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 13 (5) , 1164
Abstract
Background: The objective of our study was to investigate the impact of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, administrated early after cardiac transplantation on the occurrence of acute graft rejection (AGR) in the first 2 years post-transplant. Methods: This retrospective research was conducted in the Emergency Institute for Cardiovascular Diseases and Transplantation of Targu Mures, Romania. After applying the inclusion criteria, between January 2011 and December 2023, 36 patients fit the study design. Using Cox proportional hazards regression and Kaplan–Meier curves, we determined the time-to-event distribution, for which the first episode of AGR was considered an event, with a significance threshold of 0.05. Results: The 1-year rate of AGR was 38.9% and was 47.2% at 2 years, with a 2-year mortality of 11.1%. The interpretation of the Cox regression indicated that early initiation of spironolactone represents a protective factor against the 2-year AGR (HR: 0.263; 95%CI: 0.076–0.922; p = 0.037 by the log-rank test). Conclusions: These results might suggest a possible benefit of the early administration of spironolactone after a heart transplant, but further prospective studies need to be performed for the validation of our findings.Keywords
Funding Information
- University of Medicine, Pharmacy, Science, and Technology “George Emil Palade” of Târgu Mureș (511/1/17 January 2022)
This publication has 95 references indexed in Scilit:
- The efficacy and safety of sodium‐glucose cotransporter‐2 inhibitors in solid organ transplant recipients: A scoping reviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024
- Immunosuppressive Drugs2022
- IL-6 Directed Therapy in TransplantationCurrent Transplantation Reports, 2021
- Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trialEuropean Journal of Heart Failure, 2021
- Statin Intensity and Risk for Cardiovascular Events After Heart TransplantationESC Heart Failure, 2020
- Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantationAmerican Heart Journal, 2020
- Updates on Heart TransplantationCurrent Heart Failure Reports, 2019
- Organ Shortage: The Greatest Challenge Facing Transplant MedicineWorld Journal of Surgery, 2014
- Cellular and Functional Imaging of Cardiac Transplant RejectionCurrent Cardiovascular Imaging Reports, 2010
- Mechanism of cellular rejection in transplantationPediatric Nephrology, 2010